Royalty Pharma (RPRX) FCF Payout Ratio (2019 - 2026)

Royalty Pharma (RPRX) has 8 years of FCF Payout Ratio data on file, last reported at 0.15 in Q1 2026.

• For the quarter ending Q1 2026, FCF Payout Ratio rose 65.8% year-over-year to 0.15; the trailing twelve-month figure through Mar 2026 stood at 0.33 (down 36.88% YoY), and the FY2025 full-year result was 0.21, down 55.52% from the prior year.
• FCF Payout Ratio slipped to 0.15 in Q1 2026, from 0.44 in the prior quarter.
• In the past five years, FCF Payout Ratio ranged from a high of 0.44 in Q4 2025 to a low of 0.44 in Q2 2024.
• A 5-year average of 0.05 and a median of 0.08 in 2023 frame the typical range for FCF Payout Ratio.
• Across the five-year window, FCF Payout Ratio surged 611.91% in 2023 and plunged 881.2% in 2024, its largest moves.
• Tracing RPRX's FCF Payout Ratio over 5 years: stood at 0.1 in 2022, then plunged by 202.85% to 0.11 in 2023, then soared by 219.81% to 0.13 in 2024, then surged by 241.26% to 0.44 in 2025, then slumped by 65.6% to 0.15 in 2026.
• Business Quant data shows RPRX's FCF Payout Ratio at 0.15 in Q1 2026, 0.44 in Q4 2025, and 0.13 in Q3 2025.